Repatha Cost in California 2026: Price, Insurance, Medicaid, and Compounded Options

What Repatha Is and Why Its Price Is Complicated

Repatha (evolocumab) is a fully human monoclonal antibody that inhibits PCSK9, a protein that normally degrades LDL receptors in the liver. Blocking PCSK9 keeps more LDL receptors on liver cell surfaces, which increases clearance of LDL cholesterol from the blood. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and clinical atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy.

California has a large and payer-diverse population, spanning Medi-Cal, Covered California marketplace plans, and employer-sponsored insurance. That mix is why the price an individual Californian actually pays for Repatha can range from close to $0 to the full list price, depending on coverage, income, and which assistance programs they qualify for.

The FOURIER trial (N=27,564) found that evolocumab, given as 140 mg every two weeks or 420 mg once monthly, reduced LDL-C by a mean of 59% versus placebo (median baseline LDL-C 92 mg/dL) and reduced the risk of cardiovascular death, myocardial infarction, or stroke by 20% (HR 0.80; 95% CI 0.73-0.88; P<0.001) over a median follow-up of 2.2 years. Those results are why cardiologists often pursue coverage for eligible patients even when it requires an appeal.

What Repatha Costs in California

The manufacturer's list price (wholesale acquisition cost, or WAC) for Repatha has been reported at roughly $580 per month for both the 140 mg autoinjector regimen and the 420 mg once-monthly system. List prices change over time and are set by the manufacturer, so this figure should be confirmed against a current source, such as Amgen's own pricing disclosure or a pharmacy quote, before it is used to counsel a specific patient.

Cash price without insurance generally tracks close to list price at most retail pharmacies, though discount programs can sometimes lower it somewhat. Exact discount amounts vary by pharmacy, by month, and by which discount card is used, so a specific dollar range is not reliable to publish here without a live pricing source.

Health plans and pharmacy benefit managers typically negotiate confidential rebates with the manufacturer, so the net amount an insurer actually pays is usually lower than the published list price. Patients generally do not see that negotiated price; they see either their copay/coinsurance or, if uninsured, something close to list price.

The 2022 AHA/ACC cholesterol guideline supports adding a PCSK9 inhibitor for patients with clinical ASCVD who are at very high risk and whose LDL-C remains at or above 70 mg/dL despite maximally tolerated statin and ezetimibe therapy. That is the clinical logic prescribers cite in prior-authorization letters. The exact wording above is a paraphrase of the guideline's intent; anyone quoting the guideline directly in a PA letter or patient-facing material should confirm the precise published language rather than relying on this summary.

Does Medi-Cal Cover Repatha?

Medi-Cal covers evolocumab with prior authorization for patients with a qualifying diagnosis: established ASCVD, HeFH, or HoFH. Prior authorization is required for every new prescription.

What Medi-Cal prior authorization generally requires. Documentation typically needs to show a qualifying diagnosis, a trial of maximally tolerated statin therapy, a recent LDL-C value above the relevant guideline threshold, and that ezetimibe has been tried or is contraindicated. Research on PCSK9 inhibitor prior authorizations more broadly has found that initial denials are common and that a meaningful share succeed on appeal when documentation is complete. That research reflects national data rather than California-specific figures, and Medi-Cal's specific denial and appeal rates, if published, would need to come from the Department of Health Care Services (DHCS) or from a managed Medi-Cal plan directly.

Once approved, Medi-Cal beneficiaries typically face minimal cost sharing under standard Medi-Cal rules, though the exact copay amount should be confirmed against current DHCS policy since cost-sharing rules can change.

Medi-Cal covers a large share of California's population. Managed Medi-Cal plans (for example, LA Care, Health Net Community Solutions, and Anthem Blue Cross Medi-Cal) each run their own formulary and prior authorization process within DHCS requirements, including their own turnaround-time targets. Specific plan turnaround times change and should be confirmed with the plan rather than assumed from this article.

Commercial Insurance Coverage for Repatha in California

Major commercial insurers operating in California generally cover evolocumab on formulary, typically on a specialty tier with step therapy requirements, meaning a documented statin (and usually ezetimibe) trial before approval.

Covered California (ACA marketplace) plans. Plans sold through Covered California must cover FDA-approved PCSK9 inhibitors when medically necessary, consistent with essential health benefit requirements. Step therapy commonly requires a documented trial of a high-intensity statin and ezetimibe first. Specialty-tier copay or coinsurance amounts vary by plan and change from year to year, so a specific dollar figure should come from the patient's current plan documents rather than this article.

Employer-sponsored plans. Large California insurers, including Kaiser Permanente, generally cover evolocumab on their specialty formularies, usually with coinsurance rather than a flat copay. Coinsurance percentages and resulting monthly costs vary by employer group and plan year and should be verified against the member's current benefit summary.

The Amgen copay card. Amgen has historically offered a copay assistance card that can substantially reduce or eliminate the out-of-pocket cost for eligible commercially insured patients, with an annual cap and eligibility rules that exclude patients enrolled in government payer programs such as Medicare, Medicaid, or TRICARE. Because copay card terms, caps, and eligibility rules are updated periodically, current details should be confirmed directly through Amgen rather than assumed from a prior year's terms.

Compounded Evolocumab: Legal Status Requires Verification

Some marketing claims that compounded evolocumab is available through 503A pharmacies as a low-cost alternative to Repatha. That claim requires more scrutiny than it usually gets, and this article treats it cautiously rather than presenting it as settled.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed pharmacy may compound a preparation for an individual patient from a valid prescription, but this framework was designed around traditional small-molecule drug compounding. Evolocumab is a complex biologic, a monoclonal antibody manufactured through cell-culture processes that are difficult to replicate outside industrial biomanufacturing. The FDA has not listed evolocumab on an official 503A bulk drug substances list, and FDA guidance on compounding biologics generally has been restrictive.

This article cannot verify, from the sources available, whether any specific California-licensed 503A pharmacy currently compounds an evolocumab-related preparation, whether such a preparation would be pharmacologically equivalent to Repatha, or whether doing so is consistent with current FDA and California State Board of Pharmacy rules. No clinical trial data exist for a compounded evolocumab product; all published efficacy and safety data are for Amgen's approved product. Given the manufacturing complexity of monoclonal antibodies and the absence of trial data for any compounded version, a patient considering this route should independently verify the pharmacy's license through the California State Board of Pharmacy's license lookup, ask specifically what is being compounded and from what source material, and discuss the safety tradeoffs with their prescribing physician before proceeding. Editorial and medical review should confirm or remove this section before publication if current verification is not available.

Verification Checklist: What's Stable vs. What Changes

Before publishing or reusing figures from this article, separate facts that are unlikely to change soon from facts that are tied to a specific date and need to be re-verified.

Telehealth Prescribing of Repatha in California

California law generally permits telehealth prescribing of medications like Repatha without requiring a prior in-person visit, provided the prescribing physician establishes a valid patient-physician relationship through a real-time evaluation and documents that evaluation appropriately. A recent lipid panel is a reasonable clinical prerequisite before prescribing a PCSK9 inhibitor, whether the visit is in person or by telehealth. The specific statute section governing this, and any updates to California's telehealth parity requirements for reimbursement, should be confirmed against the current text of California law rather than assumed from this summary, since statutes are amended over time.

Patient Assistance Programs

Amgen has historically operated more than one assistance pathway for evolocumab: a copay card for commercially insured patients, an income-based free-drug program for uninsured or underinsured patients (often framed around a percentage of the federal poverty level), and periodic short-term free-trial offers for new patients. Because eligibility rules, income thresholds, and enrollment details are updated periodically, exact figures should be confirmed directly with Amgen or the prescribing physician's office rather than taken from a prior year's published terms.

Medicare beneficiaries who qualify for Extra Help (the Part D low-income subsidy) may see a reduced Part D cost share for evolocumab, though Amgen's commercial copay card generally cannot be combined with government coverage. A patient's exact savings depend on their specific Part D plan and subsidy level.

How Repatha Compares to Other LDL-Lowering Options

Understanding where evolocumab sits in the treatment sequence helps explain why insurers require step therapy before approving it.

High-intensity statins. Atorvastatin 40-80 mg and rosuvastatin 20-40 mg are generic and inexpensive at most California pharmacies. National guidelines classify these regimens as "high-intensity" because they are expected to lower LDL-C by roughly 50% on average; individual response varies. Large outcome trials, including the Cholesterol Treatment Trialists' meta-analysis of more than 90,000 patients, established that statin therapy reduces cardiovascular events in proportion to the degree of LDL-C lowering. Evolocumab is generally reserved for patients who remain above their LDL-C goal despite maximally tolerated statin therapy.

Ezetimibe. Generic ezetimibe is inexpensive and modestly lowers LDL-C further when added to a statin. Guideline-based treatment pathways generally position ezetimibe as a step before PCSK9 inhibitor initiation in most patients.

Inclisiran (Leqvio). Also a PCSK9-pathway inhibitor, but dosed as an injection roughly twice yearly after an initial dose rather than every two to four weeks. It is not available through compounding. Its price and coverage pattern should be checked directly with the manufacturer and a patient's specific plan, since neither is stable information to publish here.

Bempedoic acid (Nexletol). An oral ATP-citrate lyase inhibitor approved for patients who cannot tolerate statins or need additional lowering. Trials of bempedoic acid added to statins, including the CLEAR Wisdom trial, have shown further LDL-C reductions in roughly the mid-teens to high-teens percentage range; the exact figure depends on which trial and patient population is referenced. Current pricing should be confirmed directly rather than assumed.

Evolocumab's roughly 59% LDL-C reduction in the FOURIER trial is substantially larger than what any oral add-on therapy achieves, which is the clinical rationale cardiologists use when pursuing coverage despite cost and prior-authorization hurdles.

Steps to Pursue Repatha Coverage in California

Confirm the diagnosis and lipid values. Obtain a fasting lipid panel and document the LDL-C value alongside the current statin regimen. Confirm HeFH by clinical criteria or genetic testing, or confirm established ASCVD through medical records, as applicable.

Document the statin trial. Prior authorization generally requires evidence of a high-intensity statin trial of adequate duration, or documented statin intolerance with specific adverse events, doses, and dates if intolerance is the basis for stepping past statin therapy.

Document ezetimibe use or a documented reason it was not used. Most California payers, including Medi-Cal, expect to see a trial of ezetimibe before approving a PCSK9 inhibitor unless there is a documented contraindication.

Submit prior authorization with a letter of medical necessity. A strong letter typically references the patient's cardiovascular risk category, current LDL-C, and relevant trial evidence such as FOURIER, and should reflect the payer's actual current criteria rather than a generic template.

Apply for manufacturer assistance in parallel with prior authorization, rather than waiting for a PA decision, since enrollment timelines for a copay card and an income-based assistance program differ.

Appeal a denial if one occurs. California law gives patients the right to an independent medical review (IMR) through the Department of Managed Health Care (DMHC) when an insurer denies a medically necessary drug. The specific statutory citation and current IMR filing process and timelines should be confirmed against DMHC's current published guidance rather than assumed from this article, since administrative rules and timelines can change.

Who Generally Qualifies for Repatha

FDA labeling and national cholesterol guidelines describe three main qualifying populations.

Heterozygous familial hypercholesterolemia (HeFH). Patients with a clinical or genetic HeFH diagnosis who remain above LDL-C targets despite maximally tolerated statin and ezetimibe therapy. HeFH is commonly estimated to affect about 1 in 250 people in the general population, based on published epidemiologic research, and most people with the condition remain undiagnosed. Applying that ratio to California's population of roughly 39 million suggests well over 100,000 residents could have HeFH; this is an illustrative estimate based on national prevalence data, not an official California count.

Homozygous familial hypercholesterolemia (HoFH). A very rare condition, generally estimated at somewhere around 1 in 300,000 people depending on the study population, caused by two defective LDL receptor alleles, with baseline LDL-C values that can be extremely high. In the TESLA Part B trial (N=50), evolocumab reduced LDL-C by about 30% on average in this population, one of the few therapies shown to meaningfully lower LDL-C in HoFH.

Established ASCVD. Patients with a history of heart attack, ischemic stroke, unstable angina, coronary revascularization, or peripheral artery disease who are classified as very high risk and whose LDL-C remains at or above the guideline threshold despite maximally tolerated statin and ezetimibe therapy.

Patients outside these categories are unlikely to receive insurance approval or Medi-Cal authorization for evolocumab.